Faraday is a clinical-stage biopharmaceutical company focused on developing drugs to prevent and treat cardiac and skeletal muscle loss. FDY-5301 (our lead program in Phase 3) is being developed to address an unmet need in cardiovascular medicine: the auuenuation of reperfusion-induced damage that occurs during percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)
